This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Running the Numbers on Intercept Pharma's NASH Drug. Huge!

I just got off the phone with an institutional investor who was long Intercept Pharma (ICPT - Get Report) going into today's big NASH data win. Yes, he's incredibly happy.

He hasn't done a ton of work on obeticholic acid (OCA) in NASH -- he was more focused on the ongoing phase III study in primary billary cirrhosis -- but he has worked through some quick calculations on the commercial potential for OCA in NASH. The numbers are huge and suggest Intercept shares could go even higher. Before that happens, the company could be acquired, he believes.

Yes, he's long Intercept so talking his book to some degree, but hear him out. The story is compelling.

This is the way he looks at the market for OCA in NASH:

2-3% of the U.S. population (315 million people) are diagnosed with NASH, with 0.3% to 0.9% diagnosed with NASH that has progressed to cirrhosis. He uses the latter,  sicker patient population for his calculations because they're more likely to seek treatment. This equates to a patient population of 1.8 million people.

Assume Intercept treats 20% of these NASH+cirrhosis patients, which is 360,000 patients. 

Assume Intercept prices OCA at $10,000 per year. It's a pill and a daily, chronic treatment, so this pricing is in line with that the PCSK9s might cost. 

Calculator, please...

You're looking at a peak sales potential for OCA in U.S. NASH patients of $3.6 billion.

If you think 20% market share is too high, bring it down to 15%. That's $2.7 billion in peak sales.

How long to $2.7 billion in peak sales? Let's say five years. Sales multiple? 5x. Discount rate: 20%

The net present value of OCA in NASH is $6.75 billion. 

Even with today's huge move, Intercept's market cap is $5 billion.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs